HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Isatuximab Now FDA Approved with Kyprolis and Dex for Relapsed/Refractory Myeloma
Posted: Apr 06, 2021
Isatuximab Now FDA Approved with Kyprolis and Dex for Relapsed/Refractory Myeloma image

This week the FDA approved the use of the anti-CD38 monoclonal antibody isatuximab (Sarclisa) in combination with carfilzomib (Kyprolis) and dexamethasone for relapsed or refractory myeloma patients who received 1-3 prior therapies. 

The approval was based on the Phase III IKEMA trial which showed that IsaKd triple combination reduced the risk of myeloma progression or death by 45% compared to Kd alone. The study has not yet met the median progression-free survival at the time of study reporting.

The study also showed the following results: 

  IsaKd Kd
Overall Response Rate 86.6% 82.9%
Complete Response 39.7% 27.6%
Partial Response 33% 28.5%


Most common side effects were: 

Side Effect IsaKd Kd
Respiratory tract infection 67% 57%
Infusion related reactions 46% 3.3%
Fatigue 42% 32%
Hypertension 37% 32%
Diarrhea 36% 29%
Pneumonia 36% 30%
Dyspnea 29% 24%
Bronchitis 24% 13%
Cough 23% 15%


The most serious side effects in the isatuximab combination therapy arm were pneumonia (25%) and upper respiratory tract infections (9%).

Thomas Martin, MD and associate director and co-leader of the Hematopoietic Malignancies Program of the myeloma program at the University of California San Francisco (UCSF) said: 

“In the Phase 3 IKEMA study, the addition of Sarclisa to carfilzomib and dexamethasone reduced risk of disease progression or death by 45%. This approval is an important advancement for patients whose disease has relapsed and reinforces the potential for Sarclisa to become a standard of care in relapsed or refractory multiple myeloma.” 

Isatixumab was previously approved for use with pomalidomide and dexamethasone who had received at least two prior therapies (including lenalidomide and a proteasome inhibitor.)

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube